RxDoctor Payments Data

Melissa Hamilton

Acute Care · Tampa, FLNPI 1831720168

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Cvrx, Inc. accounts for 85.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $19,017, more than ten times the $289 reported in 2021. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,135in general payments, 2019–2025

Across 106 payments — averaging $218.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$20K
  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$687
  • Kestra Medical Technology Services, Inc.$221
  • Amgen$125
  • Abiomed$84
  • plus $349 from 8 others

What the payments were for

  • Consulting fees$12,30053%
  • Travel & lodging$7,29532%
  • Food & beverage$3,54015%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,135 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.

See all acute care providers in Florida

Medicare billing

Part B allowed, 2024
$9,321
Medicare patients
83
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan47$52,091
FarxigaDapagliflozin Propanediol32$39,807
Repatha SureclickEvolocumab13$17,714
Torsemide29$608
Potassium Chloride18$372
Bumetanide14$369
Metoprolol Succinate17$136
Furosemide17$124
Spironolactone23$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$45$52,09147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.

Other acute care in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →